Gink­go part­ners up with Sen­si­ble Biotech­nolo­gies to forge mR­NA man­u­fac­tur­ing plat­form

Since the suc­cess­ful, glob­al re­lease of mR­NA-based Covid-19 vac­cines, the mR­NA plat­form has be­come a top fo­cus for bio­phar­ma com­pa­nies. Gink­go Bioworks’ lat­est part­ner­ship looks to fur­ther tap the mR­NA mar­ket.

On Mon­day, Sen­si­ble Biotech­nolo­gies — a Eu­ro­pean-based biotech look­ing to build a cell-based plat­form to pro­duce mR­NA — and Gink­go an­nounced a part­ner­ship to de­vel­op such a man­u­fac­tur­ing plat­form. The an­nounce­ment said most of the mR­NA that is used in vac­cines and oth­er ther­a­peu­tic prod­ucts is pro­duced by in vit­ro tran­scrip­tion, which is cell-free and us­es pu­ri­fied en­zymes. The stan­dard forms of mR­NA pro­duc­tion are lim­it­ed in how much can be made and need to go through cost­ly pu­rifi­ca­tion meth­ods to elim­i­nate byprod­ucts that could cause ad­verse re­ac­tions in pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER